


**Solent Multiple Sclerosis
Therapies Limited**

**Financial Accounts for the Period Ended
31 March 2025**

Company Registration Number: 2215154

FRIDAY



AE36ERJF

A16

23/05/2025

#266

COMPANIES HOUSE

Solent Multiple Sclerosis Therapies Limited
Report and Accounts for the Period Ended 31 March 2025

CONTENTS	PAGES
Report of the Directors	1
Independent Examiner's Report	2
Statement of Financial Activities	3
Income and Expenditure Account	4
Balance Sheet	5-6
Notes to the Accounts	7-10

The following pages do not form part of the statutory accounts.

Summary Income and Expenditure Account	11
Income Detail	12
Physio/Osteo/Reflex/Shiatsu analysis	13
Bank Balances	14
Fixed Assets	15
Detailed Income and Expenditure Account	16

Solent Multiple Sclerosis Therapies Limited
Accounts for the Period Ended 31 March 2025

Trustees **R Hayter** **- Acting Chairman**

P Lee
A Alexander
S Emery
A Sandford
R Moorhead
K Ebbens
K Silman
L Rickman
C Alexander

Registered Office **Bradbury House**
56 Hewett Road
North End
Portsmouth
Hampshire
PO2 0QP

Bankers **Lloyds TSB plc**
80 London Road
North End
Portsmouth
Hampshire
PO2 0LX

Company Number **2215154**

Accountants **Hunter Simmons Ltd**
EMP Building, Unit 1
4 Solent Road
Havant
Hampshire
PO9 1JH

Solent Multiple Sclerosis Therapies Limited

Report of the Directors for the Period Ended 31 March 2025

Report of the Directors

The directors herewith present the accounts for the period ended 31 March 2025.

Activities of the Company

The company's principal activity is to aid the condition of those suffering from multiple sclerosis by providing guidance, practical support and therapy to those such persons.

Directors

The directors of the company throughout the year were as follows:

P Lee	A Alexander	R Hayter
A Sandford	S Emery	K Ebbens
C Alexander	R Moorhen	K Silman
L Clarke	L Rickman	

The directors do not hold any shares in the company.

Charitable Status

The company is a registered charity with the Charity Commissioners in England and Wales.

Company Number and Charity Number

The company registered number is 2215154 and the Registered Charity number is 299545.

Governing Document

The governing document is the Memorandum and Articles of Association.

Trustees

The directors have produced a Directors' Report as required by Company Law instead of a Trustees' Report.

Registered Office

The registered office of the charity is Bradbury House, 56 Hewett Road, North End, Portsmouth, Hampshire PO2 0QP.

Exemptions

Advantage has been taken in the preparation of the Directors' Report of the special exemptions applicable to small companies conferred by Part 15 of the Companies Act 2006.

By Order of the Board

 R Hayter - Chairman

Dated 16 MAY 2025

Independent Examiner's Report to the Trustees of Solent Multiple Sclerosis Therapies Limited

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 March 2025.

Responsibilities and basis of report

As the trustees of the Charity (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').


Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that that accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by Charities [applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)]

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Sean Hunter, FFP FIPA
Institute of Financial Accountants
Membership Number: 232174

Hunter Simmons Ltd
EMP Building, Unit 1
4 Solent Road
Havant
Hampshire
PO9 1JH

Date 16 MAY 2025

Solent Multiple Sclerosis Therapies Limited
Statement of Financial Activities
For the Period Ended 31 March 2025

	Notes	Mar-25 £	Mar-24 £
General Fund			
Incoming Resources:			
Donations:			
Donations and Gifts		155,102	145,623
Investment Income		1,209	1,650
Income from trading activities:			
Related to objects of the charity		0	0
Total incoming resources		<u>156,311</u>	<u>147,273</u>
Resources Expended:			
Direct Charitable Expenditure		56,545	47,676
Fund Raising and Publicity		11,390	6,801
Management and Administration	3	99,763	92,931
Total resources expended	4	<u>167,698</u>	<u>147,408</u>
Net incoming resources	5	(11,387)	(135)
Balances at 31 March 2024		343,285	343,420
Balances at 31 March 2025		<u>331,898</u>	<u>343,285</u>

Solent Multiple Sclerosis Therapies Limited
Income and Expenditure Account
For the Period Ended 31 March 2025

	Mar-25	Mar-24
	£	£
Total Income from continuing operations	156,311	147,273
Total expenditure from continuing operations	167,698	147,408
Net income/(expenditure) for the year	<u>(11,387)</u>	<u>(135)</u>

There are no recognised gains or losses in 2025 or 2024 other than the net income for the years.

The notes on pages 7 to 10 form part of these accounts

Solent Multiple Sclerosis Therapies Limited
Balance Sheet
As at 31 March 2025

	Notes	Mar-25		Mar-24	
		£	£	£	£
Fixed Assets					
Tangible Assets	8		209,416		219,115
Current Assets					
Stocks	9		-		-
Prepayments			3,261		3,375
Cash at Bank and in Hand			146,591		145,829
			<u>149,852</u>		<u>149,204</u>
Creditors: Amounts due within one year					
Other creditors	10		<u>8,282</u>		<u>5,946</u>
Net Current Assets			141,570		143,258
Total Net Assets			<u><u>350,986</u></u>		<u><u>362,373</u></u>
Fund Balances					
Income and Expenditure Account			331,898		343,285
Reserved Capital			3,200		3,200
Operating Reserve Account			15,888		15,888
Total Fund Balances			<u><u>350,986</u></u>		<u><u>362,373</u></u>

The Balance Sheet continues on the following page
The notes on pages 7 to 10 form part of these accounts

Solent Multiple Sclerosis Therapies Limited
Balance Sheet (continued)
As at 31 March 2025

Directors' Statement

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 relating to small companies, for the period ended 31 March 2025.

The members have not required the company to obtain an audit of its financial statements for the period ended 31 March 2025 in accordance with Section 476 of the Companies Act 2006..


The directors acknowledge their responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The accounts have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies and with the Financial Reporting Standard for Smaller Entities (effective April 2008).

These accounts were approved on 16 MAY 2025


..... R Hayter - Director


..... K Ebbens - Director

The notes on pages 7 to 10 form part of these accounts

Solent Multiple Sclerosis Therapies Limited
Notes to the Accounts
For the Period Ended 31 March 2025

1 ACCOUNTING POLICIES

Basis of Accounting

These accounts have been prepared on the basis of the historical cost convention in accordance with the Financial Reporting Standard for Smaller Entities (effective April 2008) and with applicable Accounting Standards, the Accounting and Reporting by Charities - Statement of Recommended Practice (SORP 2005) and the Charities Act 1993.

Incoming Resources

Incoming resources are reported gross.

Legacies and Donations

Legacies and donations are accounted for when the resources are receivable or when the charity's entitlement is legally enforceable. Legacies received in the form of property and investments are credited at the lower of probate and market value. Other gifts in kind are included in the accounts at market value. Assets for distribution are recognised only when distributed; assets given for use by the charity are recognised when receivable; stocks of unsold donated goods are not valued for balance sheet purposes.

Grants Receivable

Grants are recognised when receivable.

Direct Charitable Expenditure, Fund Raising, Management and Administration

Direct charitable expenditure comprises all expenditure directly relating to the objects of the charity. When necessary, costs are allocated between direct charitable expenditure fund-raising and management and administration on the basis of apportionment of the relevant expenditure.

Life Subscriptions

There are no life subscriptions

Commitments

Commitments made by the directors that are legally binding have been accrued. Those that are not legally binding have not been charged in the accounts, but disclosed in note 11.

Tangible Fixed Assets and Depreciation

Tangible fixed assets are stated at cost.

Depreciation is provided over the expected useful lives of each category of tangible fixed asset as follows:

Furniture and Office Equipment	25% on net book value
Plant and Equipment	25% on net book value
Buildings	Depreciated to reflect a valuation of £35000
Improvements to Freehold Property	2% on cost
The Compression Chamber and previous Improvements to Freehold Property are fully depreciated.	
Freehold Land has not been depreciated.	

Solent Multiple Sclerosis Therapies Limited
Notes to the Accounts
For the Period Ended 31 March 2025

1 ACCOUNTING POLICIES (continued)

Stocks

Stocks are valued at the lower of cost and net realisable value after making due allowance for any obsolete or slow-moving items. Cost includes direct materials, labour and overheads incurred in providing each service. Net realisable value is based on estimated selling price less selling costs.

Cash Flow Statement

The company has taken advantage of the exemption in the Financial Reporting Standard 1 from the requirement to disclose a Statement of Cash Flows on the grounds that it is a small company.

2 INVESTMENT INCOME

	Mar-25	Mar-24
	£	£
Bank Interest Receivable	<u>1,209</u>	<u>1,650</u>

3 MANAGEMENT AND ADMINISTRATION

	Mar-25	Mar-24
	£	£
Central Management and Administration	<u>99,763</u>	<u>92,931</u>

4 ANALYSIS OF TOTAL RESOURCES EXPENDED

	Mar-25	Mar-24
	£	£
Salaries	86,092	79,546
Utilities	3,790	3,441
Supplies	68,117	53,369
Depreciation/Loss on disposal	9,699	11,052
	<u>167,698</u>	<u>147,408</u>

5 NET INCOMING RESOURCES

	Mar-25	Mar-24
	£	£
This is stated after charging:		
Depreciation/Loss on disposal	<u>9,699</u>	<u>11,052</u>

Solent Multiple Sclerosis Therapies Limited
Notes to the Accounts
For the Period Ended 31 March 2025

6 INTEREST PAYABLE LESS RECEIVABLE

	Mar-25	Mar-24
	£	£
Bank Interest Receivable	<u>1,209</u>	<u>1,650</u>

7 TAXATION

No corporation tax is payable as the company is a registered charity.

8 TANGIBLE FIXED ASSETS

	Imp's to Freehold Property	Freehold Property	Com- pression Chamber	Plant and Equipment	Furniture and Office Equipment	Total
Cost						
Brought Forward	254,222	39,884	22,244	69,226	6,576	392,152
Additions						-
Disposals				- 7,150	-	7,150
Carried Forward	<u>254,222</u>	<u>39,884</u>	<u>22,244</u>	<u>62,076</u>	<u>6,576</u>	<u>385,002</u>
Depreciation						
Brought Forward	80,317	4,884	22,244	62,511	3,081	173,037
Charge for the year	5,084			1,680	874	7,638
Eliminated on disp's				- 5,089	-	5,089
Carried Forward	<u>85,401</u>	<u>4,884</u>	<u>22,244</u>	<u>59,102</u>	<u>3,955</u>	<u>175,586</u>
Net Book Value						
At 31.03.25	<u>168,821</u>	<u>35,000</u>	<u>-</u>	<u>2,974</u>	<u>2,621</u>	<u>209,416</u>
At 31.03.24	<u>173,905</u>	<u>35,000</u>	<u>-</u>	<u>6,715</u>	<u>3,495</u>	<u>219,115</u>

The Improvements to Freehold Property represent the costs incurred for the major refurbishment of the Therapy Centre at Hewett Road, North End, Portsmouth.

The works were completed in 2008.

9 STOCK

	Mar-25	Mar-24
	£	£
Goods for resale	<u>-</u>	<u>-</u>

Solent Multiple Sclerosis Therapies Limited
Notes to the Accounts
For the Period Ended 31 March 2025

10 CREDITORS: AMOUNTS DUE WITHIN ONE YEAR

	Mar-25	Mar-24
	£	£
Taxation and social security	1,779	4,852
Accruals	3,667	1,094
Other creditors	<u>2,836</u>	<u>-</u>
	<u>8,282</u>	<u>5,946</u>

11 LIMITED LIABILITY

Every member of the company undertakes to contribute to the assets of the company, in the event of the company being wound up, an amount not exceeding £1.

Solent Multiple Sclerosis Therapies Limited
Summary Income and Expenditure Account
For the Period Ended 31 March 2025

	Mar-25	Mar-24
	£	£
Income	156,311	147,273
	<u>156,311</u>	<u>147,273</u>
Expenditure		
Oxygen	9,519	8,207
Splints	0	0
Salaries	86,092	79,546
Building and Equipment Repairs and Renewals	12,860	13,195
Utilities	3,790	3,441
General Office and Running Costs	12,367	8,931
Insurance Premiums	4,512	4,294
Diet Supplements, Vitamins and Goods for Resale	537	838
Provision of Physio and Therapists	20,410	11,504
Fund Raising Expenses	6,612	5,127
Professional Fees	1,300	1,273
HMRC Penalty	0	0
Depreciation	9,699	11,052
	<u>167,698</u>	<u>147,408</u>
Net Surplus/(Deficit) for the Year	<u><u>(11,387)</u></u>	<u><u>(135)</u></u>

Solent Multiple Sclerosis Therapies Limited
Income Detail
For the Period Ended 31 March 2025

	Mar-25	Mar-24
	£	£
Bank interest	1,209	1,650
Book sales (Ziffit)	364	364
Bonus ball	1,256	920
Collections	354	1,005
Community events	21,025	6,759
Corporate grants	7,474	11,644
Direct debit donations	1,626	1,445
Ebay/Vinted/Charity Shop	19,442	15,445
EPO/APS/Masks	969	1,506
Gift aid	3,162	2,394
HDOT donation	63,430	68,587
Individual donations	4,695	5,747
Inductions	3,358	2,625
Masons donations	-	-
Membership	7,454	6,580
National lottery grant	-	-
Office bottles	2,960	506
Physio donation	7,952	5,353
Portsmouth lottery	260	328
Reflex donations	7,767	7,169
Solar panel payment	1,484	1,923
Sponsored events	70	5,323
Trust donations	-	-
	<u>156,311</u>	<u>147,273</u>

Solent Multiple Sclerosis Therapies Limited
Therapy Analysis
For the Period Ended 31 March 2025

	Donations	Costs	Surplus/ (Deficit)
	£	£	£
Physio	7,952	6,670	1,282
Osteo	0	0	0
Reflex	7,767	6,703	1,064
	<u>15,719</u>	<u>13,373</u>	<u>2,346</u>

Solent Multiple Sclerosis Therapies Limited
Bank Analysis
For the Period Ended 31 March 2025

	Mar-25	Mar-24
Lloyds TSB		
Current account	58,015	8,378
CAF Bank accounts		
CAFCash account	-	22,493
Scottish Widows Bank	1,069	1,053
Air Receiver & Deluge Tank Fund	-	26,864
HDOT chamber emergency replacement reserve	87,215	86,415
Paypal	88	14
Total Bank Balances	<u>146,387</u>	<u>145,217</u>
Cash in hand	204	612
Total Bank and Cash	<u>146,591</u>	<u>145,829</u>
Balance per accounts	146,591	145,829

Solent Multiple Sclerosis Therapies Limited
Fixed Assets
For the Period Ended 31 March 2025

	Imp's to Freehold Property	Freehold Property	Com- pression Chamber	Plant and Equipment	Furniture and Office Equipment	Total
Cost						
Brought Forward	254,222	39,884	22,244	69,226	6,576	392,152
Additions	-	-	-	-	-	-
Disposals	-	-	-	7,150	-	7,150
Carried Forward	<u>254,222</u>	<u>39,884</u>	<u>22,244</u>	<u>62,076</u>	<u>6,576</u>	<u>385,002</u>
Depreciation						
Brought Forward	80,317	4,884	22,244	62,511	3,081	173,037
Charge for the year	5,084	-	-	1,680	874	7,638
Eliminated on disp's	-	-	-	5,089	-	5,089
Carried Forward	<u>85,401</u>	<u>4,884</u>	<u>22,244</u>	<u>59,102</u>	<u>3,955</u>	<u>175,586</u>
Net Book Value						
At 31.03.25	<u>168,821</u>	<u>35,000</u>	<u>-</u>	<u>2,974</u>	<u>2,621</u>	<u>209,416</u>
At 31.03.24	<u>173,905</u>	<u>35,000</u>	<u>-</u>	<u>6,715</u>	<u>3,495</u>	<u>219,115</u>

Solent Multiple Sclerosis Therapies Limited
Detailed Income and Expenditure Account
For the Period Ended 31 March 2025

		Mar-25	Mar-24
		£	£
Income		156,311	147,273
		<u>156,311</u>	<u>147,273</u>
Direct Costs			
Fund Raising Costs		6,612	5,127
Provision of Physio and Therapists	20,410		
less contribution	<u>0</u>	20,410	11,504
Oxygen	9,519		
less contribution	<u>0</u>	9,519	8,207
Splints		0	0
EPO		537	838
Payroll Costs		<u>86,092</u>	<u>79,546</u>
		<u>123,170</u>	<u>105,222</u>
Gross Surplus		<u>33,141</u>	<u>42,051</u>
Overheads			
Building and Equipment Repairs and Renewals		12,860	13,195
Utilities		3,790	3,441
General Office and Running Costs		12,367	8,931
Professional Fees		1,300	1,273
HMRC Penalty		0	0
Depreciation/Loss on disposal		9,699	11,052
Insurance		<u>4,512</u>	<u>4,294</u>
		<u>44,528</u>	<u>42,186</u>
Net Surplus/(Deficit) for the year		<u><u>(11,387)</u></u>	<u><u>(135)</u></u>
Building and Equipment Repairs and Renewals			
Repairs and Maintenance			
Building		8,745	13,915
Chamber		<u>4,115</u>	<u>0</u>
		<u>12,860</u>	<u>13,915</u>
General Office and Running Costs			
Staff Training		1,022	0
Miscellaneous		1,103	848
Telephone		819	994
Postage and Stationery		708	480
Computer Costs		4,223	3,472
Subscriptions		480	220
Bank charges		323	314
Cleaning and Hygiene		<u>3,689</u>	<u>2,603</u>
		<u>12,367</u>	<u>8,931</u>